Interview with Chen Chun Lin, Co-Chairman, Medicilon/MPI Preclinical Research…
You completed your higher education in the US and worked there for a period afterwards; what caused you to move…
Medicilon/MPI Preclinical Research Shanghai
Last updated: 13.02.2014
Address: 585 Chuanda Road, Pudong New AreaShanghai, 201200,China
Tel: +86 21 31268381
Web: http://www.medicilon-mpi.com/
Company description
As a newly formed joint venture located in China, Medicilon/MPI Preclinical Research Shanghai provides a portfolio of preclinical discovery and development services to pharmaceutical and biotechnology companies.
Medicilon/MPI Preclinical Research Shanghai has brought together the best of its parent companies, Shanghai Medicilon and MPI Research, to assure top quality, on-time GLP and non-GLP studies.
Products and services
toxicology services
Interviews
Related
China / Boehringer Ingelheim's Stroke Rehab Centre Success & Continuing China Push
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai…
Haijun Dong – CEO, BioDuro-Sundia
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of…
China / Public Insurance Coverage for Rare Disease Patients: Beijing & Shanghai Surprisingly Low in New City Ranking
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the…
China / AstraZeneca/Junshi anti-PD-1 Tie-Up; New UK Biologics Plan for Pharmaron; Clover’s $230 Million Investment Boost
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and…
China / Yangtze River Pharmaceutical Group (YRPG) in Profile
One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River…
China / HiFiBiO CEO on the Keys to Global Biotech Success
HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T:…
China / New Drug Approvals 2020
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi…
Liang Schweizer – CEO & CSO, HiFiBiO Therapeutics
Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the…
China / National Reimbursement Drug List (NRDL) 2020: What Reward for Innovation?
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact…
China / New Year, New Round of Drug Price Cuts
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug…
China / 5 Top Trends in Healthcare & Biopharma in 2020
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being…
Global / 2020's Top 7 Biotech IPOs In Profile
Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of…
